There are two observations to make from the way Duesberg argues the case. First, he discusses how and when AZT was first discovered and its mechanism of action inhibiting DNA synthesis, then cites some anecdotal cases, and concludes that all ARV drugs are toxic and not useful. Mechanisms of action are interesting to scientists but this is the wrong evidence to evaluate for efficacy. If one were to ask how best to treat hypertension, for example, the answer does not come from the interesting neurobiology of the hypothalamic blood pressure control centers, the crystal structure of angiotensin, or how Captopril was initially discovered.
The relevant standard of proof, the gold standard, is the clinical trial where the drug in question is compared to placebo (or alternative treatments) in a randomized controlled manner and a priori chosen outcomes analyzed]. This is why the US Food and Drug Administration requires clinical trial data before licensing any new drug. By choosing mechanisms of action, Duesberg is using inappropriate evidence, but purposefully so as to obfuscate the argument.
After deciding on the standard of proof—which is the clinical trial—the second step is to agree on how to assess the results from many such trials done in different countries and populations. Duesberg’s method is narration, where he ignores the data he dislikes, cherry-picks the statements he likes from different publications, and selectively interprets them to support his position, disregarding even the main conclusions of the studies.
Narrative reviews, while very common and perhaps relatively less demanding to perform, have the drawback that it may be unclear whether all the relevant evidence has been used or the reviewer selected studies that support a desired conclusion, and whether the apportionment of weight to studies was based on objective criteria such as sample size. The relevant standard here is a meta-analysis, that is, a systematic review with statistical synthesis of all relevant available data. When a meta-analysis is performed well, there is an a priori protocol specifying the question asked, the databases to be searched for publications, justifiable inclusion and exclusion criteria, the data to be extracted from studies, the quality assessment score to be used for each study, and models for statistical analysis.
For Duesberg to convince impartial readers that ARVs are useless or toxic when used for PMTCT and AIDS treatment, he has to produce a properly conducted meta-analysis (the objective standard for summarizing evidence) of clinical trials (the highest grade of evidence for assessing efficacy) where the drugs were used. Obviously, he cannot produce this because numerous clinical trials and meta-analyses have already been conducted and the evidence, as shown below, is unanimous in that the benefits of ARVs outweigh the side effects.
To quote an example from our work, we recently published ‘‘Efficacy of Antiretroviral Drugs in Reducing Mother-to-Child Transmission of HIV in Africa: A Meta-Analysis of Published Clinical Trials.’’ The question asked was how efficacious have ARVs been in PMTCT in Africa, first to generate an efficacy estimate directly relevant for policies on the continent that is worst affected by HIV/AIDS, and second, to pre-empt the debate on what is feasible in Africa (due to drug compliance, C-section rates, breastfeeding, late antenatal presentation, etc.) by considering only studies performed in Africa. The key result of this meta-analysis is that ARVs reduce mother-to-child transmission of HIV from 21% (combined placebo estimate) to 10.6% (combined ARVs estimate) at 4–6 weeks after birth. From all the studies that reported toxicity, ARV regimens for PMTCT are well tolerated by both the mothers and babies.
The quantity of this evidence is 10 clinical trials with a combined sample size of over 7,000 HIV-infected pregnant women, and over 800 transmission endpoints. The type of evidence is high grade, that is, randomized clinical trials rather than observational, cross-sectional, or case reports. The Jadad quality of the individual clinical trials is high.
The efficacy of using ARVs versus placebo is 50%. Using the US Institute of Medicine categories of certainty in assessing evidence, the evidence establishes that ARVs are efficacious in reducing MTCT in Africa, and the evidence favors rejection of the hypothesis that ARVs, in the doses used, are toxic to the mothers or babies. Example diagrams are shown in the published paper [click here]
Contrary to what Duesberg suggests, there are unanimous data (all trials conducted in Africa published by December 2006) to demonstrate the usefulness of ARVs in PMTCT in Africa, and other groups have arrived at the same conclusions for ARV use in PMTCT generally.
Likewise, extensive clinical trials data demonstrate the efficacy of ARV drug combinations in treating AIDS. The results from use of drugs in combination were so dramatic that the term ‘‘HAART,’’ for Highly Active Anti-Retroviral Therapy, was coined. Many systematic reviews have been conducted and updated by the Cochrane Collaboration and other groups, and the data are unanimous regarding efficacy. In addition, data are now available from the use of ARVs at the program level in African countries and these support the efficacy observed in clinical trials. Several studies have systematically reviewed the data just for developing countries and Africa, and others compared low and high-income countries.
In short, if Duesberg wishes to demonstrate that certain ARVs are no better or worse than placebo or other treatments, he has to conduct a meta-analysis that considers all available evidence, rather than his approach of discussing the molecular biology of DNA chain termination and somehow inferring that ARVs are not beneficial.
Moreover, for Duesberg to totally discredit the paper on the human cost of not using ARVs, he has to argue that all ARVs are totally ineffective when used for AIDS treatment and PMTCT because if some ARVs are even marginally effective, then it means that some South Africans could have benefited, however, small the benefit, had Mbeki not obstructed drug use.
Population Growth and AIDS Deaths
The third of Duesberg and colleagues’ arguments is that there is no evidence of large-scale deaths in South Africa, and therefore whatever policies Mbeki implemented, they did not lead to deaths. To support this, they present two arguments: one, that the population of South Africa increased over the last 30 years, and two, the statistics of reported AIDS deaths in South Africa. Regarding the first argument, it is true that the population of South Africa increased over the last 30 years. The population in a country is determined by the balance between the number of live births, the total number of deaths, and net migration. Without doing an analysis of the above determinants, it not possible to use such aggregate population trend data to infer that the number of AIDS deaths was small. If this reasoning is sound, then it should be applicable to other countries and diseases as well. Is it logical to infer that AIDS deaths are few in any country that has increased its population over the last three decades?
Similarly, is it logical to infer that there has been no increase in the number of persons dying of cardiovascular diseases and cancer or that the absolute numbers of death from these diseases are small in the US, whose population has increased over the last half century?
This argument does not support Duesberg’s assertions at all. The second part of the argument quotes Statistics South Africa, which recorded an average of 12,000 deaths per year in South Africa between 1997 and 2006. The shortfall is that these data are ‘‘Findings from Death Notification.’’ First, as explained by surveillance experts, ‘‘In resource-poor countries with underdeveloped health infrastructures, reports of AIDS or HIV cases are usually not complete enough to be considered reliable measures of the scope of the epidemic’’. This simply means that the death notification system in South Africa had/has much underreporting. Indeed, the ‘‘former so called independent homelands of Transkei, Boputhatswana, Venda and Ciskei (TBVC) were not included in the reporting system until 1994’’ when the reporting system began centralization, and a new death certificate was introduced in 1998 to improve reporting.
The second shortfall is that of misclassification of deaths. AIDS patients die of the resulting opportunistic infections and cancers, and these immediate causes of death are often recorded without noting the underlying acquired immunodeficiency. According to the Medical Research Council (SA), up to 61% of HIV deaths are misclassified and the majority of them are recorded as tuberculosis and lower respiratory tract infections, which become the leading causes of death. It is apparent that Duesberg selected highly deficient statistics. [This section continues. Click here to download the entire article]
Implications
There are several implications to draw from this work. First is the translation of denialism into public health practice. One of Duesberg’s first papers questioning whether HIV causes AIDS was published in the prestigious journal Science in 1988. Some researchers initially took this as a genuine scientific debate but as Koch’s postulates were fulfilled, randomized controlled trials demonstrated the high efficacy of ARV, there was much success in PMTCT, and studies elucidated the dynamics between virus and CD4 cells, Duesberg maintained his arguments and it became clearer that he was not just a dissident scientist but a denialist. When Mbeki took up the denialists’ position in 2000, there was international outcry.
Not only was he lending his ear to discredited scientists, but AIDS denialism was crossing into national health policy through a head of government. Participants at the 2000 International AIDS Conference in Durban (SA), news outlets, scientific journals, and the public were outraged and some went as far as saying that South Africa was tripping into anarchy, descending into an abyss. South Africa did descend into that abyss. Mbeki withdrew support from clinics that had started using ARVs, restricted use of donated ARVs, obstructed Global Fund grants, and generally delayed implementing a national ARV program. Two independent studies have estimated that Mbeki’s policies led to at least 330,000 premature deaths. When AIDS denialism infiltrates public health practice, the consequences are tragic.
The second implication follows directly from the first and concerns accountability. Mbeki implemented negligent policies that led to the premature death of hundreds of thousands. His reasons, as stated by himself and health minister Tshabalala-Msimang, were that he questioned whether HIV causes AIDS and whether ARVs are safe, and neither ever publicly backed down from this thinking. The science behind Mbeki was Duesberg and other denialists.
Duesberg is still arguing for AIDS denialism and defending Mbeki and the policies that led to more than 330,000 deaths. By any reasonable standard, this requires some form of accountability.
Seth Kalichman has likened the AIDS denialists to the Holocaust deniers and Edwin Cameron likened letting AIDS patients die without medications to those who silently enabled the evils of Nazi Germany and apartheid South Africa to go unchecked.
John Moore and Nathan Geffen have called for AIDS denialists to be put on trial and Mark Wainberg has argued that denialists should be charged with public endangerment and ‘‘people like Peter Duesberg belong in jail.’’
Zachie Achmat has called for a commission of enquiry such as the Truth and Reconciliation Commission that was tasked with handling the apartheid era crimes. For how are South Africans ever going to trust their health system again?
How can a modern government be penetrated by denialists to the extent of implementing policies that kill hundreds of thousands?
William Makgoba suggested that impeding AIDS treatment was collaborating in committing genocide, and
Wycliffe Muga has asked whether Mbeki’s killing of 330,000 by obstructing life-saving medications is much different from Sudan’s President al Bashir’s killing a similar number in Darfur through obstructing humanitarian aid and militias. Is this not a crime against humanity?
Does the International Criminal Court not have a role, for it was established to handle those cases where national courts may be unable or unwilling to prosecute?
Whatever the most appropriate avenue is, what seems apparent is the need for accountability.
The third implication somewhat generalizes the argument. AIDS denialists are dangerous to the general population; many have been persuaded into risky behaviors, ineffective alternative remedies, and other harmful actions, although there is no easy way of evaluating how many. Similarly, denialists can impact public or national health policy and South Africa is one extremely tragic case.
However, denialists seem ineffective against physicians as a group. The reason is that if an AIDS patient goes to a physician, and the physician decides not to treat, the physician is held for malpractice. The medical profession is practiced only by those who have earned defined credentials. The standards of practice are generally known and deviant practitioners are disciplined by the medical societies and deregistered by states.
Moreover, the law of torts offers patients a private right of redress against negligent doctors. The above seem absent in public and global health. The practitioners are ill defined and there are no laws restricting practice to persons with specified credentials. The concept of standards of practice is not well developed, and there are no bodies tasked with self-regulation and discipline.
The concept of public health malpractice has not yet been developed. Thus, at a general level, AIDS denialism in South Africa has also exposed the deficiencies of public health practice—it is open to unqualified practitioners, negligent policies go unchecked, and the consequences are tragic. How to rectify this is beyond the scope of this paper; here it suffices to point out the deficiencies of public health in terms of standards, practitioners, and accountability, as exposed by the South Africa example.
Last, Duesberg was able to publish his paper (which was later withdrawn) only because it was not reviewed by peers knowledgeable on the subject. Denialist writings require close scrutiny and peer review before being published in scientific journals, especially when they have the potential to impact public health practice.
When AIDS denialism enters public health practice, the consequences are tragic. The implications start in honest science but extend to the need for accountability and, perhaps, public health reform.
You can download the entire pdf of this article FREE at AIDS and Behavior's website.